863579-14-0

Upstream product

• 494799-19-8 methyl 2-bromo-3-cyclohexyl-1H-indole-6-carboxylate 
• 25015-63-8 4,4,5,5-tetramethyl-[1,3,2]-dioxaboralane 
• 73183-34-3 bis(pinacol)diborane 
• 494799-18-7 methyl 3-cyclohexyl-1H-indole-6-carboxylate 

Downstream Products

• 863579-26-4 3-cyclohexyl-2-{2-[2-(tetrahydropyran-2-yloxy)ethylsulfanyl]phenyl}-1H-indole-6-carboxylic acid methyl ester 
• 877380-95-5 methyl 2-(2-acetylphenyl)-3-cyclohexyl-1H-indole-6-carboxylate 
• 877278-54-1 2-(3-chloropyrazin-2-yl)-3-cyclohexyl-1H-indole-6-carboxylic acid methyl ester 
• 877277-80-0 3-cyclohexyl-2-[4-iodo-1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-imidazol-5-yl]-1H-indole-6-carboxylic acid methyl ester 
• 877277-06-0 methyl 3-cyclohexyl-2-(4,5-dibromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-2-yl)-1H-indole-6-carboxylate 
• 1169857-89-9 C₃₄H₄₆N₂O₄Si 
• 1169856-87-4 2-(4-tert-butoxycarbonylamino-1,2,3,4-tetrahydroquinolin-8-yl)-3-cyclohexyl-1H-indole-6-carboxylic acid methyl ester 
• 1169856-94-3 3-cyclohexyl-2-[(R)-4-((R)-2-methylpropane-2-sulfinylamino)-1,2,3,4-tetrahydroquinolin-8-yl]-1H-indole-6-carboxylic acid methyl ester 
• 877269-03-9 13-cyclohexyl-6,7-dihydro-5H-pyrido[3',2':3,4]azepino[1,2-a]indole-10-carboxylic acid 
• 877272-62-3 methyl 1-(2-amino-2-oxoethyl)-2-(3-bromopyridin-2-yl)-3-cyclohexyl-1H-indole-6-carboxylate 
• 877272-52-1 methyl 1-allyl-3-cyclohexyl-2-(2-vinylpyridin-3-yl)-1H-indole-6-carboxylate 
• 877272-47-4 methyl 2-(3-bromopyridin-2-yl)-3-cyclohexyl-1H-indole-6-carboxylate 
• 877272-42-9 methyl 3-cyclohexyl-2-(2-formylfuran-3-yl)-1H-indole-6-carboxylate 
• 877280-14-3 methyl 1-(2-(benzyloxy)ethyl)-2-(2-(benzyloxy)pyridin-3-yl)-3-cyclohexyl-1H-indole-6-carboxylate 

Relevant academic research and scientific papers

The synthesis of novel heteroaryl-fused 7,8,9,10-tetrahydro-6H-azepino[1,2- a]indoles, 4-oxo-2,3-dihydro-1H-[1,4]diazepino[1,7-a]indoles and 1,2,4,5-tetrahydro-[1,4]oxazepino[4,5-a]indoles. Effective inhibitors of HCV NS5B polymerase

Three synthetic approaches have been developed that allow efficient access to novel heteroaryl fused indole ring systems, including: 7,8,9,10-tetrahydro- 6H-azepino[1,2-a]indoles, 4-oxo-2,3-dihydro-1H-[1,4]diazepino[1,7-a]indoles and 1,2,4,5-tetrahydro-[1,4]oxazepino[4,5-a]indoles. Each strategy is fully exemplified and the relative merits and limitations of the approaches are discussed. The hepatitis C virus (HCV) non-structural 5B (NS5B) polymerase inhibitory activities of select examples from each molecular class are briefly presented.

POLYCYCLIC VIRAL INHIBITORS

Disclosed are compounds and compositions of Formula (A) and their uses for treatingFlaviviridae family virus infections.

Inhibitors of HCV replication

Indole compounds of Formula I are described. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. Different forms and compositions comprising the compounds are also described as well as methods of preparing the compounds.

Discovery of conformationally constrained tetracyclic compounds as potent hepatitis C virus NS5B RNA polymerase inhibitors

We report a new series of hepatitis C virus NS5B RNA polymerase inhibitors containing a conformationally constrained tetracyclic scaffold. SAR studies led to the identification of 6,7-dihydro-5H-benzo[5,6][1,4]diazepino[7,1-a]indoles (19 and 20) bearing a basic pendent group with high biochemical and cellular potencies. These compounds displayed a very small shift in cellular potency when the replicon assay was performed in the presence of human serum albumin.